We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Compugen Ltd | NASDAQ:CGEN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.09 | 2.05 | 2.10 | 184 | 13:02:24 |
Compugen Ltd. (NASDAQ: CGEN) today announced that Dr. John Hunter of Compugen USA, Inc. will present at the Washington BioLeaders Forum 2014 to be held next week in Washington, D.C. In his talk, which is scheduled for January 28 in the Phacilitate Immunotherapy Forum track, Dr. Hunter will demonstrate how Compugen has applied its predictive discovery platforms to identify novel immune checkpoints for targeted antibody immunotherapy in cancer. Validation data for representative targets discovered by the Company will also be presented. Dr. Hunter is Site Head & Vice President, Antibody Research & Development at Compugen USA, Inc., a wholly owned subsidiary of Compugen Ltd.
The Immunotherapy Forum 2014, which in previous years was held in Barcelona, is an annual international conference focusing on key emerging trends in novel immunotherapeutic modalities, including checkpoint inhibitors, adoptive T-cell therapies, other cancer vaccine technologies and oncolytic virus therapeutics. This is the first year that the forum is being held as part of the annual Washington BioLeaders Forum.
About CompugenCompugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company's business model includes collaborations covering the further development and commercialization of product candidates at various stages from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2012, Compugen established operations in California for the development of oncology and immunology monoclonal antibody therapeutic candidates against Compugen drug targets. For additional information, please visit Compugen's corporate website at www.cgen.com.
Compugen Ltd.Tsipi Haitovsky, Global Media Liaison+972-52-598-9892tsipih@netvision.net.il
1 Year Compugen Chart |
1 Month Compugen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions